2002
DOI: 10.1016/s0959-8049(02)00457-4
|View full text |Cite
|
Sign up to set email alerts
|

The role of new agents in the treatment of non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
25
0
2

Year Published

2003
2003
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(27 citation statements)
references
References 141 publications
0
25
0
2
Order By: Relevance
“…The number of lung cancer patients are increasing annually. Therapeutic approaches, such as chemotherapy, radiotherapy, and surgery have been widely used to treat lung cancer; however, these treatments offered little survival rate due to severe toxicity and drug resistance (Broker et al, 2002;Singh et al, 2008). Therefore, understanding of the carcinogenic mechanisms and genes involved in lung cancer cell's fast growth is of much importance in developing more precise treatments compared to conventional treatment methods.…”
Section: Introductionmentioning
confidence: 99%
“…The number of lung cancer patients are increasing annually. Therapeutic approaches, such as chemotherapy, radiotherapy, and surgery have been widely used to treat lung cancer; however, these treatments offered little survival rate due to severe toxicity and drug resistance (Broker et al, 2002;Singh et al, 2008). Therefore, understanding of the carcinogenic mechanisms and genes involved in lung cancer cell's fast growth is of much importance in developing more precise treatments compared to conventional treatment methods.…”
Section: Introductionmentioning
confidence: 99%
“…In view of the fact that only one patient received more than four cycles of therapy, no conclusions on the cardiotoxic potential of the drug can be drawn at this time. The issue of cardiotoxicity will therefore be re-addressed in forthcoming phase II trials (Broker and Giaccone, 2002).…”
mentioning
confidence: 99%
“…Por esta razão, as epotilonas apresentam atividade superior ao paclitaxel em células resistentes, sendo que estes resultados foram, posteriormente, confirmados por cientistas da GBF 15 . Após os bons resultados preliminares, a epotilona B passou com sucesso por testes clínicos de fase I, estando atualmente em fase II 11,18 .…”
Section: Epotilonasunclassified